San Diego-primarily based Viking Therapeutics marked itself as a significant competitor during the weight loss drug market place in February after revealing promising details from the mid-phase trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in